Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07106268

Aqueous Humor Proteome in Retinal Vein Occlusion With Macular Edema

the goal of this observational study is to the find the molecular mechanisms underlying the prognosis process of Retinal vein occlusion in patients with retinal vein occlusion . The main question it aims to answer is:

What are the changes in protein in the aqueous humor during treatment in patients who are sensitive to anti-VEGF drug therapy?

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Retinal Vein Occlusion Cardiovascular Diseases Embolism and Thrombosis Eye Diseases Retinal Diseases Thrombosis Vascular Diseases Venous Thrombosis

Age range

20 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Tianjin medical university eye hospital

Tianjin, Province, 300384, China

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Cystic or diffuse edema in the macular area, retinal vein tortuous dilation with hemorrhage
  • Optical coherence tomography (OCT) examination showed that the macular area was raised, edema and thickened
  • Monocular disease, baseline central retinal thickness (CRT) ≥ 250mm
  • Intravitreal injection, laser photocoagulation and blood circulation and blood stasis removal drugs were not treated before surgery
  • The patient had normal blood pressure, negative urine protein, normal liver and kidney function, and normal electrocardiogram

Exclusion criteria

  • Patients with fluorescein fundus angiography (FFA) showing a large area (10 optic disc areas) without perfusion requiring retinal photocoagulation
  • Patients with chronic dacryocystitis, glaucoma, cataract, severe proliferative vitreoretinopathy or vitreous hemorrhage, epi macular membrane or macular ischemia, diabetic retinopathy, age-related macular degeneration, ocular trauma and other diseases
  • Intravitreal therapy or laser photocoagulation with corticosteroids or anti-VEGF drugs within three months before the study

Treatment and study plan

Primary outcomes

  1. Central retinal thickness

    Time frame: March 2023 - June 2024

    The Heidelberg Optical Coherence Tomography scanner was used to detect the central retinal thickness in patients

Secondary outcomes

  1. Best corrected visual acuity

    Time frame: March 2023 - June 2024

    BCVA was measured using logarithm of the minimum angle of resolution (LogMAR) chart

Sponsors and collaborators

Lead sponsor

Tianjin Medical University Eye Hospital

Other

Registry information

Official study title

Aqueous Humor Proteome Analysis in Conbercept-treated Retinal Vein Occlusion With Macular Edema

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
Aug 6, 2025
Registry last updated
Aug 7, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.